Atlas Trials

Anlotinib Combined With Sintilimab as Second-line Treatment or Beyond in Patients With Small Cell Lung Cancer

Clinical trial NCT04192682 · UNKNOWN

Trial details

NCT number
NCT04192682
Sponsor
Changzhou Cancer Hospital of Soochow University
Status
UNKNOWN
Phase
Phase 2, Phase 3
Study type
INTERVENTIONAL
Small Cell Lung Cancer
Start date
2019-05-08
Primary completion
2021-03-01
Enrollment
40

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.